News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

GlaxoSmithKline (GSK) (Jobs) Says FDA has Questions on Restless Legs Drug



8/13/2007 7:51:41 AM

NEW YORK (Reuters) - U.S. regulators have concluded that GlaxoSmithKline's (GSK.L: Quote, Profile, Research) Requip CR extended-release tablets to treat moderate-to-severe primary restless legs syndrome must meet additional conditions before getting final approval, the company said on Friday.

Read at Reuters

Related News

comments powered by Disqus
Reuters
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES